These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12505024)

  • 1. Predicting the transmission of drug-resistant HIV: comparing theory with data.
    Blower SM; Aschenbach AN; Kahn JO
    Lancet Infect Dis; 2003 Jan; 3(1):10-1. PubMed ID: 12505024
    [No Abstract]   [Full Text] [Related]  

  • 2. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco.
    Smith RJ; Okano JT; Kahn JS; Bodine EN; Blower S
    Science; 2010 Feb; 327(5966):697-701. PubMed ID: 20075214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saquinavir: an HIV proteinase inhibitor.
    Bragman K
    Adv Exp Med Biol; 1996; 394():305-17. PubMed ID: 8815695
    [No Abstract]   [Full Text] [Related]  

  • 4. [The 39th ICAAC (San Francisco) and the 7th European Conference on Clinical Aspects and Treatment of HIV-infection (Lisbon). HIV infection: antiretroviral agents in the development and trial stage].
    Duval X
    Presse Med; 2000 Feb; 29(5):253-6. PubMed ID: 10701407
    [No Abstract]   [Full Text] [Related]  

  • 5. The brightening future of HIV therapeutics.
    Greene WC
    Nat Immunol; 2004 Sep; 5(9):867-71. PubMed ID: 15334078
    [No Abstract]   [Full Text] [Related]  

  • 6. Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease.
    Bilello JA; Drusano GL
    J Infect Dis; 1996 Jun; 173(6):1524-6. PubMed ID: 8648237
    [No Abstract]   [Full Text] [Related]  

  • 7. Conference looks at HIV drug resistance.
    Chang HE
    GMHC Treat Issues; 1995 Sep; 9(9):6-8. PubMed ID: 11362910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-HIV drug development: future prospect and problems].
    Baba M
    Nihon Rinsho; 1993 Sep; 51 Suppl():357-63. PubMed ID: 7505851
    [No Abstract]   [Full Text] [Related]  

  • 9. Resistance: a shifting paradigm.
    Jenny-Avital ER
    AIDS Clin Care; 2002 Dec; 14(12):106. PubMed ID: 12510656
    [No Abstract]   [Full Text] [Related]  

  • 10. New resistance score for tipranavir.
    Poveda E
    AIDS Rev; 2008; 10(2):127. PubMed ID: 18615125
    [No Abstract]   [Full Text] [Related]  

  • 11. Interview with Celia Schiffer.
    Schiffer C
    Future Med Chem; 2013 Jul; 5(11):1193-7. PubMed ID: 23859201
    [No Abstract]   [Full Text] [Related]  

  • 12. Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.
    Bagaglio S; Messina E; Uberti-Foppa C; Merli M; Torre LD; Lazzarin A; Hasson H; Morsica G
    J Antimicrob Chemother; 2013 Jun; 68(6):1448-50. PubMed ID: 23390206
    [No Abstract]   [Full Text] [Related]  

  • 13. Challenges in the therapy of HIV infection.
    Yarchoan R; Mitsuya H; Broder S
    Immunol Today; 1993 Jun; 14(6):303-9. PubMed ID: 8397771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics.
    Ding AA; Wu H
    Math Biosci; 1999 Aug; 160(1):63-82. PubMed ID: 10465932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of molecular dynamics and free energy perturbation calculations in anti-human immunodeficiency virus drug design.
    McCarrick MA; Kollman P
    Methods Enzymol; 1994; 241():370-84. PubMed ID: 7854189
    [No Abstract]   [Full Text] [Related]  

  • 17. Highlights of the Fourth International Workshop on HIV Drug Resistance.
    Lange JM; deJong MD
    J Int Assoc Physicians AIDS Care; 1995 Aug; 1(7):25-7. PubMed ID: 11362748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of protease resistance during simplification therapy with lopinavir/ritonavir alone.
    Sprinz E; Jeffman M
    HIV Clin Trials; 2007; 8(2):105-6. PubMed ID: 17507327
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug resistance and treatment of experienced patients.
    Gallant JE
    Hopkins HIV Rep; 2003 Mar; 15(2):8-9. PubMed ID: 12739503
    [No Abstract]   [Full Text] [Related]  

  • 20. Challenges in the therapy of HIV infection.
    Yarchoan R; Mitsuya H; Broder S
    Trends Pharmacol Sci; 1993 May; 14(5):196-202. PubMed ID: 8212316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.